STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development

Area of Science:

• Immunology
• Oncology
• Vascular Biology

Background:

• Tertiary lymphoid structures (TLS) mimic lymph nodes in peripheral tissues during inflammation.
• TLS are critical for B and T cell responses, involving dendritic cells (DC) and high endothelial venules (HEV).
• TLS presence in tumors correlates with patient survival and immunotherapy response.

Purpose of the Study:

• To review the role of STING agonists in promoting TLS formation within the tumor microenvironment (TME).
• To discuss the potential of STING agonists in combination immunotherapy strategies.

Main Methods:

• Review of existing literature on TLS, tumor microenvironment, vascular normalization, and STING agonists.
• Analysis of clinical correlations between TLS and therapeutic outcomes.
• Exploration of therapeutic strategies targeting DC, vascular endothelial cells (VEC), and cytokines/chemokines.

Main Results:

• STING agonists, originally anti-angiogenic, promote vascular normalization (VN) in tumors.
• STING agonists enhance the development of a pro-inflammatory TME, DC and VEC maturation, and TLS formation.
• These effects suggest STING agonists can therapeutically reinforce TLS within the TME.

Conclusions:

• STING agonists show promise in promoting therapeutic TLS formation via vascular normalization.
• Targeting TLS formation with STING agonists could enhance immunotherapy efficacy.
• Combination approaches involving STING agonists warrant further investigation for improved cancer treatment.